Medtech deal activity has remained brisk throughout the summer after a busy start to 2026.
In recent months, several companies announced or closed acquisitions worth more than $1 billion, with Tempus agreeing to buy cancer blood test maker Personalis for $1.5 billion and investment firm KKR planning to buy device manufacturer Integer Holdings for $5.7 billion. Danaher also closed its $9.9 billion buyout of patient monitoring firm Masimo.
The two largest acquisitions of 2026 made headlines at the start of the year, when Boston Scientific announced plans to buy Penumbra for $14.5 billion and Abbott closed its $21 billion purchase of cancer test firm Exact Sciences.
Several medtech firms have also announced major divestitures in the past year. BD sold its biosciences and diagnostics businesses to Waters and Medtronic completed its spinoff of diabetes tech business MiniMed. Johnson & Johnson has also shared plans to divest its orthopedics segment.
Here are the top M&A deals so far this year:
